Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Contingent consideration liabilities by Year
Contingent consideration liabilities — Noncurrent ($M) ($M)
Vertex Pharmaceuticals Contingent consideration liabilities: $79M in FY2025, up 2.7% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Fair Value Measurements Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration liabilities — Noncurrent ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79 | +2.7% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 76.9 | -0.6% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 77.4 | -32.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 114 | -38.7% | Form 10-K (filed 2024-02-15) ↗ |
| FY2021 | Dec 31, 2021 | 187 | -1.6% | Form 10-K (filed 2023-02-10) ↗ |
| FY2020 | Dec 31, 2020 | 190 | +7.4% | Form 10-K (filed 2022-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 177 | – | Form 10-K (filed 2021-02-11) ↗ |
| FY2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2020-02-13) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Contingent consideration liabilities ($M), annual FY2018–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/cc-liab-nc
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.